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Abstract
Background: The indirect comparison of two interventions can be valuable in many situations. However, the quality of an
indirect comparison will depend on several factors including the chosen methodology and validity of underlying
assumptions. Published indirect comparisons are increasingly more common in the medical literature, but as yet, there are
no published recommendations of how they should be reported. Our aim is to systematically review the quality of
published indirect comparisons to add to existing empirical data suggesting that improvements can be made when
reporting and applying indirect comparisons.
Methodology/Findings: Reviews applying statistical methods to indirectly compare the clinical effectiveness of two
interventions using randomised controlled trials were eligible. We searched (1966–2008) Database of Abstracts and Reviews
of Effects, The Cochrane library, and Medline. Full review publications were assessed for eligibility. Specific criteria to assess
quality were developed and applied. Forty-three reviews were included. Adequate methodology was used to calculate the
indirect comparison in 41 reviews. Nineteen reviews assessed the similarity assumption using sensitivity analysis, subgroup
analysis, or meta-regression. Eleven reviews compared trial-level characteristics. Twenty-four reviews assessed statistical
homogeneity. Twelve reviews investigated causes of heterogeneity. Seventeen reviews included direct and indirect
evidence for the same comparison; six reviews assessed consistency. One review combined both evidence types. Twenty-
five reviews urged caution in interpretation of results, and 24 reviews indicated when results were from indirect evidence by
stating this term with the result.
Conclusions: This review shows that the underlying assumptions are not routinely explored or reported when undertaking
indirect comparisons. We recommend, therefore, that the quality of indirect comparisons should be improved, in particular,
by assessing assumptions and reporting the assessment methods applied. We propose that the quality criteria applied in
this article may provide a basis to help review authors carry out indirect comparisons and to aid appropriate interpretation.
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Introduction
Systematic reviews of randomised controlled trials are the
highest quality evidence to support healthcare decisions. When the
relative effectiveness of interventions is of interest, evidence from
trials that compare the interventions directly (head-to-head trials)
and evidence from indirect comparisons may be sought within a
review. A systematic review of randomised controlled trials that
directly (head-to-head) compare two interventions would generally
be regarded as the highest quality evidence to support healthcare
decisions on the comparative effectiveness of two interventions. In
many clinical areas this high quality evidence may not exist or may
be inconclusive and utilising alternative sources of evidence such as
an indirect comparison could be appropriate. For example,
pharmaceutical companies may be reluctant to compare a new
drug against the effective standard drug in a head-to-head trial in
case results do not favour the new drug. Furthermore, indirect
evidence can be more reliable than direct evidence in some cases,
for instance, when direct evidence is biased due to the
methodological inadequacies of trials that compare the treatments
directly [1]. To illustrate an indirect comparison, suppose that the
comparison between two interventions, A and B, is of interest. If
both interventions (A and B) have at some point been compared
with a third common intervention (denoted C) in separate
randomised controlled trials, then an indirect comparison is
possible. If trials exist that compare A and B directly, then direct
evidence also exists in addition to the indirect evidence.
Numerous approaches exist to undertake an indirect compar-
ison, a review of which has been undertaken by Glenny et al, who
recommend that the indirect comparison methodology should
preserve the within-trial randomisation [2]. Examples of ap-
proaches within this framework include:
(i) the ‘adjusted’ method by Bucher et al [3];
(ii) meta-regression [2];
(iii) hypothesis tests, that test for a difference between treatments
effects of A relative to C and B relative to C [4,5];
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e11054(iv) examination of the overlap of confidence intervals for
treatments effects of A relative to C and B relative to C [4].
In contrast, the ‘naive’ method would compare treatment A
against treatment B ignoring treatment C and therefore break
within trial randomisation. Naive indirect comparison methods are
therefore not recommended and are considered to be equivalent to
observational data and subject to similar biases [2,3].
The core assumption underlying indirect comparison method-
ology is similarity of treatment effects [6]. Thus, the true treatment
effect comparing any two interventions would be similar across all
trials irrespective of whether they included one or both of those
interventions. If the similarity assumption is violated, the validity
of the result of the indirect comparison is questionable. Since the
treatment effect A relative to C is not actually observed in the B vs.
C trials (except when three-arm trials are included), the similarity
assumption is difficult to assess. No well-established methods exist
to determine when the similarity assumption holds; however,
comparing patient or trial characteristics across the trials involved
in the indirect comparison, and investigating the effect of patient
or trial characteristics on the indirect comparison result using
subgroup analysis, sensitivity analysis, or meta-regression, may
indicate whether similarity is reasonable [7].
Other key assumptions that underlie indirect comparison
methodology are homogeneity and consistency. Homogeneity
concerns the similarity within the head-to-head A vs. C trials, and
the similarity within the head-to-head B vs. C trials. Standard
methods to assess homogeneity exist [4]. Consistency refers to the
similarity of direct and indirect evidence for the same treatment
comparison. Methods to assess consistency for indirect compar-
isons have been proposed [2,8,9].
The assumptions of similarity, homogeneity and consistency can
be thought of as an extension of the usual homogeneity assumption
in standard meta-analysis. Assessment of the assumptions is vital to
ensure the results of indirect comparisons are valid and interpreted
appropriately. Since no guidelines concerning the reporting of
indirect comparisons and assessment methods exist, the impor-
tance of a review of the reporting and methodological quality of
the indirect comparison methods applied in published reviews is
clear.
Existing research articles have summarised the indirect
comparison methodology applied in published reviews and
relevant methodological problems. Recently, Song et al published
a summary of methodological problems identified by surveying
published reviews of mixed treatment comparison meta-analysis.
The methodological problems reviewed were: the mixed treatment
comparison method used; whether the similarity assumption and
consistency assumption was mentioned; whether efforts were made
to investigate or improve the similarity for mixed treatment
comparisons; and whether direct and indirect evidence was
combined or compared [6]. Additionally, Edwards et al searched
for systematic reviews that included indirect comparisons of
treatments and methodological articles concerning indirect
comparisons. The various indirect comparison methods applied
in the published reviews were summarised along with discussion
about the pros and cons of each specific method [10]. Also,
Glenny et al searched for reviews that applied indirect comparison
methodology and summarised the methods and results of the
reviews [2].
The primary aim of this article is to report a systematic review
of the reporting and methodological quality of published indirect
comparisons using specifically devised quality assessment criteria.
These criteria may provide a basis for the future development of a
quality assessment tool for the evaluation and critical appraisal of
indirect comparisons to aid appropriate interpretation. The review
also adds empirical data to the existing evidence and highlights
further the importance of improving reporting quality with some
preliminary recommendations made.
Methods
Eligibility criteria
Inclusion Criteria:
(i) Reviews that applied statistical methods to indirectly
compare the clinical effectiveness of two interventions (A
and B) based on randomised controlled trials.
(ii) An intervention is defined to be any treatment, dose,
treatment regimen, or clinical procedure.
(iii) A review was considered to have applied statistical
m e t h o d st om a k ea ni n d i r e c tc o m p a r i s o nw h e na
quantitative summary of the indirect comparison of two
interventions was produced or a description of the overlap
of confidence intervals was given.
(iv) An individual review may include more than one indirect
comparison of two interventions provided separate analy-
ses were undertaken and presented.
Exclusion Criteria:
(i) Review protocols or abstracts.
(ii) Methodological publications that presented indirect com-
parisons for illustrative purposes.
(iii) Cost effectiveness reviews.
(iv) Narrative reviews of trials, meta-analyses, treatment
policies, or available treatments.
(v) Reports of a single trial.
(vi) Reviews that did not compare interventions (e.g. reviews
that compared different populations of patients).
(vii) Indirect comparisons based on non-randomised trials.
(viii) Reviews that indirectly compared interventions qualita-
tively (i.e. did not apply statistical methods).
(ix) Reviews that indirectly compare more than two interven-
tions simultaneously (for example using mixed treatment
comparison meta-analysis).
Search strategy
The following databases were searched using specific search
terms (Table S1): The Database of Abstracts and Reviews of
Effects (DARE) (1994 to March 2008), The Cochrane library
(March 2008), and Medline (1966 to March 2008). Reviews were
sought regardless of language. Duplicate citations were excluded.
Review selection
The full publication was obtained for each review located by the
search and independently assessed against the eligibility criteria by
two reviewers using an eligibility form. After assessment,
differences in the assessment results were discussed. Reports were
scrutinised to ensure that only the latest version of updated reviews
was included.
Data extraction
Information was extracted using a data extraction form
regarding: general characteristics of the reviews, such as, the
inclusion criteria in terms of patients, interventions, trial design, and
primary outcomes; the indirect and direct comparisons made; the
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data and measure of effect for the primary outcome; and whether
the review was based on individual patient data or aggregate data.
We also extracted information regarding the indirect compar-
ison method; the consideration and assessment of the similarity,
homogeneity, and consistency assumptions; reporting of results;
and interpretation of the evidence. More specifically, we extracted
the indirect comparison method reported or applied and the type
of results presented (e.g. measure of effect, confidence interval, p-
value, number of trials, number of patients). Regarding the
similarity assumption, we extracted information such as: the
assumption’s phrasing; any reported assessment methods; whether
sensitivity analysis, subgroup analysis, or meta-regression was
applied to investigate if the indirect comparison result varied; any
remarks regarding the results of such methods; and whether
patient or trial characteristics across all trials included in the
indirect comparison were reported, compared, or comparable. For
the homogeneity assumption, we extracted details such as: the
assumption’s phrasing; the assessment method reported or applied;
whether the homogeneity assumption was satisfied based on
quantitative results or concluding statements; whether a fixed
effects or random effects model was applied; whether sensitivity
analysis, subgroup analysis, or meta-regression was applied across
trials in each trial set involved in the indirect comparison; and any
remarks regarding the results of these methods. Regarding the
consistency assumption, we extracted information such as: the
assumption’s phrasing; the assessment method reported or applied;
whether the assessment method was satisfied based on quantitative
results or concluding statements; whether direct and indirect
evidence was combined and the type of results presented (e.g.
measure of effect, confidence interval, p-value, number of trials,
number of patients); whether patient or trial characteristics across
all trials were reported, compared, or comparable; whether three-
arm trials were included using direct evidence rather than indirect
evidence from the trial; reasons given for using indirect and direct
evidence; and whether results from each head-to-head trial were
reported. For reporting of results we extracted details, such as,
whether the meta-analytic result for each of the two trial sets
involved in the indirect comparison was presented and the type of
results given (e.g. treatment effect estimate, confidence interval, p-
value, number of trials, number of patients); whether results from
all the individual trials’ were reported and the type of results given
(trial arm summary data or treatment effect estimates); and
whether the review indicated which results were based on indirect
evidence. Regarding interpretation we extracted information, such
as, whether the review indicated that direct and indirect evidence
are not equivalent; and whether the review indicated that more
head-to-head trials were needed.
The data extracted related to the review’s primary outcome
where stated, or the outcome for which results were reported first
in the absence of a specific primary outcome. When reviews did
not specifically report the number of trials (or patients) in the
indirect comparisons the number of trials (or patients) were
calculated based on the data from direct comparisons. The review
author was not contacted in the case of unclear or missing data as
it was considered that the quality assessment should be based solely
on the reported information.
Data analysis and quality assessment
The general characteristics of reviews were summarised.
Categorical data were summarised using frequencies.
We independently assessed the quality of the reporting and
application of indirect comparison methods in each review using
specific quality criteria. Differences in the assessment results were
discussed. Initially, the criteria were compiled from recommenda-
tions given in published literature [1–5,8,9,11]. The feasibility of
the assessment was tested by one author by pre-piloting the initial
criteria. The criteria were then condensed and adapted to focus on
the main points of interest. For example, we disregarded a
criterion that considered whether the indirect comparison method
had been specifically reported in the review and instead focussed
on whether the method applied maintained randomisation by
recalculating the indirect comparison to determine the method
applied or otherwise (see criterion 1 in Table 1). The final criteria
focus on six quality components: indirect comparison method;
consideration and assessment of the similarity, homogeneity, and
consistency assumptions; reporting of results; and interpretation of
evidence. The final criteria are displayed in Table 1. Reviews were
classified as yes (representing higher quality), no (representing
lower quality), or unclear for each criterion. The proportions and
percentage of reviews were calculated for each classification for
each criterion.
We considered higher quality reviews to be reviews that applied
indirect comparison methods that preserved randomisation and
that presented a measure of treatment effect and measure of
precision. Regarding similarity, reviews were classed as higher
quality when they stated the similarity assumption and a method
to assess the assumption; applied a suitable assessment method,
such as, sensitivity analysis, subgroup analysis or meta-regression
including all the trials in the indirect comparison; and presented
and compared patient or trial characteristics for all trials in the
indirect comparisons. Regarding homogeneity, we considered
higher quality reviews to be reviews that applied a suitable method
to assess homogeneity (such as the chi-square test, I-square
statistic, or estimating the between trial variance in a random
effect model) and if heterogeneity was evident that it was
accounted for using a random effects model and explored using
sensitivity analysis, subgroup analysis or meta-regression. Regard-
ing consistency, reviews were classed as higher quality when they
assessed consistency; did not combine indirect and direct evidence
in the presence of inconsistency; and compared patient or trial
characteristics for all trials contributing direct and indirect
evidence. We classed reviews that included three arm trials as
lower quality when the review author ignored the direct evidence
in the trial. We classed reviews as higher quality when justification
for including direct and indirect evidence was given; and when the
results from trials contributing direct evidence were presented.
Regarding interpretation, we considered reviews to be of higher
quality when the review author explained that direct and indirect
comparisons are not equivalent to avoid misinterpretation of the
results; and when the review author considered the strength of
direct evidence. For reporting, reviews were judged to be of higher
quality when the review author presented the two meta-analytic
results used in the indirect comparison and the individual trials’
results; and when the review author indicated when results of
indirect comparisons were reported.
Results
Figure 1 displays the review selection process. The 43 included
reviews were published in 35 English language journals between
1992 and 2007 (Figure 2) [12–54].
See Table S2 for the characteristics of included reviews.
Most indirect comparisons (30 reviews) were based on fewer
than 15 trials. The indirect comparisons made are reported in
Table S2.
Reviews were focussed in a variety of clinical areas: circulatory
(11 reviews); musculo-skeletal (nine reviews); reproductive (four
Indirect Comparisons
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Criteria Yes (%) No (%) Unclear (%)
Not
applicable
Indirect comparison method
Is the method applied to undertake the indirect comparison adequate?
(1) 41 (95) 2 (5) 0 (0) 0
If an adequate method is used, is a treatment effect estimate and measure
of precision reported?
25 (61) 16 (39) 0 (0) 2
Similarity
Is the assumption of similarity stated? 11 (26) 32 (74) 0 (0) 0
Is a method described to assess the similarity assumption within
the review methods section?
(2)
0 43 (100) 0 (0) 0
Is a reasonable approach used to assess the assumption of similarity?
(3) 19 (44) 22 (51) 2 (5) 0
Are patient or trial characteristics reported for all trials in the indirect comparison? 38 (88) 5 (12) 0 (0) 0
Are patient or trial characteristics compared across the two trial sets
involved in the indirect comparison?
11 (26) 32 (74) 0 (0) 0
Are patient or trial characteristics reported to be comparable for
the two trial sets involved in the indirect comparison?
4 (9) 5 (12) 34 (79) (2 unclear
if comparable;
32 not reported)
0
Homogeneity across trials within each of the two trial sets involved in the indirect comparison
Is the method used to determine the presence of statistical
heterogeneity adequate?
(4)
24 (60) 12 (30) 4 (10) 3
Is the homogeneity assumption satisfied or is statistical heterogeneity
accounted for if present?
(5)
19 (48) (8
homogeneous;
11 accounted)
3 (8) 18 (45) (17 unclear
if homogeneous; 1
unclear if accounted)
3
If the homogeneity assumption is not satisfied, is clinical or
methodological homogeneity across trials in each trial set involved
in the indirect comparison investigated by an adequate method?
(6)
12 (38) 19 (59) 1 (3) 11
Consistency
Is consistency of effects assessed?
(7) 6 (35) (1used
statistical method)
11 (65) 0 (0) 26
If the direct and indirect evidence is reported to be consistent,
is the evidence combined and the result presented?
(8)
1 (25) 3 (75) 0 (0) 39
If inconsistency is reported, is this accounted for by not combining
the direct and indirect evidence?
(9)
2 (100) 0 (0) 0 (0) 41
Are patient or trial characteristics compared between direct
and indirect evidence trials?
(10)
5 (29) 12 (71) 0 (0) 26
Are patient or trial characteristics for direct and indirect
evidence trials reported to be comparable?
(11)
2 (12) 1 (6) 14 (82) (2 unclear
if comparable;
12 not reported)
26
Are any included 3-arm trials correctly analysed?
(12) 3 (25) 9 (75) 0 (0) 31
Is justification given for using indirect evidence and direct evidence?
(13) 8 (47) 9 (53) 0 (0) 26
Does the review present results from all trials providing direct evidence ?
(14) (65) 6 (35) 0 (0) 26
Interpretation
Is a distinction made between direct comparisons and indirect comparisons? 25 (58) 18 (42) 0 (0) 0
Does the review state that more trials providing direct evidence are needed? 24 (56) 19 (44) 0 (0) 0
Reporting
Does the review present both of the meta-analysis results from
each of the two trial sets involved in the indirect comparison?
37 (86) 6 (14) 0 (0) 0
Was it highlighted which results were from indirect evidence?
(15) 24 (56) 19 (44) 0 (0) 0
Are the individual trials’ treatment effect estimates reported? 23 (53) 20 (47) 0 (0) 0
(1)Yes: method preserves randomization. No: method does not preserve randomization.
(2)Yes: reported a method that is stated will assess the assumption of similarity. No: do not report a method.
(3)Yes: sensitivity analysis, subgroup analysis, or meta-regression used to assess consistency of the indirect comparison across different trial or patient characteristics. No:
no method, no analysis that includes all the trials in the indirect comparison. Unclear: unclear if the trials used in the analysis are the same trial sets involved in the
indirect comparison.
(4)Yes: Chi-square test, I-squared statistic, estimating the between trial variance from a random effects models. No: no method applied, or not applied to the two trial
sets contributing to the indirect comparison. Unclear: unclear if heterogeneity was assessed for the two trial sets contributing to the indirect comparison. Not
applicable: only one trial in each trial set.
(5)Yes: no heterogeneity present (reported by authors or determined from the results), or accounted for heterogeneity using the random effects model. No:
heterogeneity not accounted for using the random effects model. Unclear: unclear if heterogeneity present, or unclear if heterogeneity taken into account using the
Indirect Comparisons
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doi:10.1371/journal.pone.0011054.g001
random effects model. Not applicable: only one trial in each trial set.
(6)Yes: sensitivity analysis, subgroup analysis, or meta-regression used to assess homogeneity across different trial or patient characteristics within each of the two trials
sets involved in the indirect comparison. No: no method, no analysis that includes the trials in each of the two trial sets involved in the indirect comparison. Unclear:
unclear if the trials used in the sensitivity analysis, subgroup analysis, or meta-regression are the same set of trials as those in each of the two trial sets involved in the
indirect comparison. Not applicable: only one trial in each trial set; or homogeneity assumption satisfied.
(7)–(14)Not applicable: both indirect and direct evidence are not presented for the same comparison.
(8)Not applicable: reported to be inconsistent, or unclear if consistent based on text or results.
(9)Not applicable: reported to be consistent, or unclear if inconsistent based on text or results.
(12)Yes: three-arm trials are correctly analysed i.e. indirect evidence (AC, BC) is not included and direct evidence (AB) is analysed, and data from a three-arm trial is not
combined as though it is from two different studies. No: three-arm trials are incorrectly analysed i.e. indirect evidence (AC, BC) is included and direct evidence (AB)i s
not analysed, or data from a three-arm trial is combined as though it is from two different studies. Na: no three-arm trials are included in the review.
(15)Yes: the term indirect comparison is stated when referring to the result or the result is presented under a heading that states the result is based on an indirect
comparison. No: result is presented without noting it is an indirect comparison.
doi:10.1371/journal.pone.0011054.t001
Table 1. Cont.
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(two reviews); gastrointestinal (two reviews); post-operative (two
reviews); psychiatric (two reviews); diabetes (one review); ocular
(one review) and other clinical areas (three reviews). A range of
outcomes were studied in the reviews as described in Table S2.
Dichotomous outcome data predominated (32 reviews) with
treatment effects summarised using the risk ratio (16 reviews), the
odds ratio (13 reviews), or the risk difference (three reviews);
continuous outcomes were presented using the mean difference
(six reviews) and the standardised mean difference (three reviews);
count data were reported using the rate ratio (one review); and
time to event data were summarised with the hazard ratio (one
review). One review stated that individual patient data were
analysed but the remainder were based on aggregate data.
A variety of interventions were compared indirectly. Thirty-four
reviews indirectly compared pharmacological treatments: drugs
(20 reviews), doses or regimens (seven reviews), and drug
combinations (seven reviews). Nine reviews compared non-
pharmacological interventions: vitamin/mineral supplements
(two reviews), testing methods (two reviews), and treatment
delivery (five reviews).
Quality assessment
Table 1 displays the quality assessment results. Refer to Table
S3 for the quality assessment results for each criterion for each
review.
Indirect comparison methodology. Adequate statistical
methods, that is, methods that preserved randomisation within
trials, were applied in 41 reviews (95%): 23 reviews applied the
adjusted method, six reviews used meta-regression, five reviews
compared the overlap of confidence intervals, and seven reviews
used significance tests. Two reviews (5%) applied inadequate
methods (naı ¨ve method).
Of the 41 reviews that used adequate methods, only 25 (61%)
presented a measure of treatment effect and its precision for the
indirect comparison (22 used the adjusted method, three used
meta-regression).
Similarity. The similarity assumption was stated in 11
reviews (26%) using various terminology and described in
different sections of the review manuscript; the assumption was
described in the introduction (one review), methods (two reviews),
results (two reviews), discussion (five reviews), and appendix (one
review) (Table 2).
None of the reviews explicitly described a method to examine
the assumption of similarity within the methods section. However,
19 reviews (44%) did apply reasonable methods to explore this
assumption:
(i) grouping the trials according to a particular characteristic,
indirectly comparing interventions for each grouping (i.e.
subgroup analysis) (seven reviews);
(ii) conducting meta-regression including trial-level summaries
that may modify the treatment effect (four reviews);
(iii) selecting a trial group based on a particular characteristic
and indirectly comparing interventions using the selected
trial subset (i.e. sensitivity analysis) (eight reviews).
Analyses varied greatly in terms of the number of variables
studied.
A summary of patient and trial characteristics were presented in
38 reviews (88%), although the number of characteristics varied
substantially across reviews. Only eleven reviews (26%) compared
characteristics between the two trials sets contributing to the
indirect comparison: four reviews reported that characteristics
were comparable; five reviews stated characteristics were dissimilar
(characteristics described as being dissimilar included: study
duration, disease severity, dose, and outcome definition) but
continued to estimate the indirect comparison; and two reviews
did not state whether or not characteristics were comparable, thus
were unclear regarding comparability, but did discuss the
similarities and differences of characteristics among the trials.
Figure 2. Frequency of published reviews including indirect comparisons, by year of publication.
doi:10.1371/journal.pone.0011054.g002
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treatment comparison therefore homogeneity assessment was not
applicable. To determine the presence of heterogeneity, 24 reviews
(60%) implemented adequate methods, namely the Chi-squared
test, I-squared statistic, or estimation of between-trial variability.
Twelve reviews (30%) did not report an adequate method or
results of a homogeneity assessment for the relevant group of trials.
The assessment method was unclear or it was unclear whether the
assessment had included the group of trials of interest in four
reviews (10%).
Based on the I-squared statistic, Chi-square test, or statements
reported, the homogeneity assumption seemed reasonable in eight
reviews. There was evidence of heterogeneity in 15 reviews, 11 of
which applied a random effects model. In seventeen reviews
homogeneity was not tested or reported, hence the presence of
homogeneity was unclear.
For the 32 reviews for which statistical heterogeneity may exist,
twelve reviews (38%) implemented adequate methods: subgroup
analysis (seven reviews), sensitivity analysis (two reviews), or meta-
regression (three reviews) to explore clinical and/or methodolog-
ical factors as a potential explanation of statistical heterogeneity
within the trial sets. Nineteen reviews (59%) did not explore
potential causes of heterogeneity for relevant trial groups. One
review (3%), classified as unclear, did not indicate the trial set on
which the assessment was applied.
Consistency. Seventeen reviews (40%) included direct and
indirect evidence in the review for the same comparison. Six of
these reviews (35%) assessed consistency of the treatment effects:
one review used a hypothesis test to compare the direct and
indirect estimates of treatment effect; and five reviews discussed
the consistency of direct and indirect treatment effects. Eleven of
the reviews (65%) did not assess consistency of the treatment
effects.
Of the six reviews that did evaluate consistency, four reported
consistent evidence and two reported inconsistency. One review
that reported consistency combined direct and indirect effect
measures using meta-analysis to produce a pooled effect estimate.
Both of the reviews that reported inconsistency investigated
differences and did not combine evidence types.
Patient and trial characteristics were compared across direct
and indirect evidence trials in five reviews (29%) of which two
reported comparability, one reported non-comparability, and two
did not report results.
Twelve reviews included information from three-arm trials, but
only three of these reviews (25%) correctly analysed these data as
direct evidence rather than indirect evidence.
Justification for including indirect evidence and direct evidence
was provided in eight reviews (47%), reasons were: limited number
of trials providing direct evidence (five reviews), aimed to compare
direct and indirect evidence (two reviews), and both reasons (one
review).
Six reviews (35%) did not present the results from each trial
contributing direct evidence.
Interpretation. Twenty-five reviews (58%) made a distinction
between indirect comparisons and direct comparisons. Twenty-four
reviews (56%) stated that more direct evidence trials were needed.
Reporting. Thirty-seven reviews (86%) presented meta-
analysis results from each of the two trial sets involved in the
indirect comparison. Twenty-four reviews (56%) highlighted when
the result was an indirect comparison by stating this term with the
result. The treatment effect estimated from each trial was reported
in 23 reviews (53%).
Table 2. Phrasing of the similarity assumption.
Review Phrasing of the similarity assumption
Berner 2006 ‘‘The chosen procedure bases on the assumption, that agents are comparable through their relative effect vs. a common comparator’’ (methods).
Boonen 2007 ‘‘The validity of an adjusted indirect comparison depends on the internal validity of the RCTs involved. The methodology assumes similarity in trial design
and methodological quality. Another assumption is that the magnitude of the treatment effect is consistent in patients across different trials’’
(discussion).
Chou 2006 ‘‘that the relative effect of one treatment compared with another is consistent across the entire set of trials’’ (introduction).
Clark 2004 ‘‘For the adjusted indirect comparison to be valid, the key underlying assumption is that the relative efficacy of an intervention is consistent in patients
included in different trials; that is, that the estimated relative efficacy is generalisable’’ (results).
Collins 2007 ‘‘However, this method is only valid when the magnitude of the treatment effect is consistent between the different studies being compared’’
(appendix).
Hochberg
2003
‘‘The authors did note that there were several assumptions that should be fulfilled in order to support the inferences drawn from these comparisons,
including similarity of methodology in trial design and measurement of clinically important outcomes, and consistency of treatment effect in different
subgroups of patients’’ (discussion).
Jones 2004 ‘‘However, the method is only valid when the magnitude of the treatment effect is consistent between the different studies being compared’’ (results).
Lim 2003 ‘‘The validity of indirect comparison meta-analysis is built on the assumption that no important differences exist between trials examining medium or
low dose regimens. If the two sets of trials differ with respect to a feature (clinical or methodological) that modified the treatment effect, then the
comparisons of medium and low dose aspirin would be confounded’’ (discussion).
Otoul 2005 ‘‘In order for this indirect comparison to be valid, the overall characteristics of the trials included in the meta-analyses could not differ systematically. The
main statistical assumption in this adjusted method is that the relative effect of a drug is consistent; i.e., the odds ratio is the same in patients included in
different trials’’ (methods).
Sauriol 2001 ‘‘The indirect approach to meta-analysis requires certain conditions to yield optimal results. For example, it is important that study designs, patient
inclusion/exclusion criteria, and patient characteristics at baseline are as similar as possible across studies. Heterogeneity in study design or study
population can lead to heterogeneity in results, and may lead to nonvalid conclusions. Therefore, the use of such methods does not always lead to the
same conclusions’’ (discussion).
Zhou 2006 ‘‘The presence of clinical heterogeneity in these trials was evident; however, results from meta-analysis and substudies, particularly those using individual
patient data, have indicated that the RR reduction of cardiovascular events by statin did not depend on the patients’ risk stratified by age, sex, CHD
history, and other cardiovascular risk factors. This consistency in the effect across different baseline characteristics is also required by the method of
adjusted indirect comparison to ensure valid results’’ (discussion).
doi:10.1371/journal.pone.0011054.t002
Indirect Comparisons
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Recommendations to review authors
Guidelines for reporting conventional pair-wise meta-analyses
and for producing high quality systematic reviews are already
available [4,55]. This review identifies a clear need to extend such
guidelines to indirect comparisons, focussing on the assessment of
the underlying assumptions. The quality criteria applied in this
article may provide a basis for the future development of a quality
assessment tool for the evaluation and critical appraisal of indirect
comparisons to aid appropriate interpretation. Key recommenda-
tions based on published literature [1–5,8,9] and expert opinions
are given below to help review authors carry out indirect
comparisons and to aid appropriate interpretation.
Firstly, the method of analysis, the assumptions made and
methods for assessing the plausibility of assumptions, particularly
that of similarity should be clearly stated within the methods
section of the report. We found that 11 reviews (26%) stated the
similarity assumption and even fewer reviews stated the homoge-
neity assumption and consistency assumption. No review explicitly
mentioned the use of a particular method to assess the assumption
of similarity.
Although a formal statistical test for similarity is not available,
there are approaches that can be used to assess how reasonable is
the assumption. The similarity assumption holds when the true
treatment effects comparing any two interventions (i.e. A vs. C, B
vs. C, and A vs. B) would be similar across all trials irrespective of
which interventions where included in the trial (A, B, or C). If the
true treatment effect comparing any two interventions is modified
by a particular trial or patient characteristic and all the trials
involved in the indirect comparison are not alike with respect to
the characteristic, then the assumption will be violated. One
approach to assess the similarity assumption is to compare patient
characteristics and trial features descriptively across all trials
contributing to the indirect comparison. This can help identify
variability in any important characteristic that could modify the
treatment effects and hence violate the similarity assumption. If
characteristics are similar, the similarity assumption is more likely
to hold than if characteristics are dissimilar. However, if
characteristics vary but are not expected to modify treatment
effects then the assumption may still be satisfied. This of course
assumes that there are no unknown characteristics that would
modify the result. The characteristics studied should be chosen
using expert, evidence-based information, as should be the case in
any standard meta-analysis. In our review, only 11 reviews (26%)
undertook some kind of comparison of trial or patient character-
istics. Bucher et al compared characteristics across the two trial sets
(A vs. C and B vs. C) by calculating a summary measure for each of
the trial sets and then comparing the summary measures [3]. No
review followed the method as applied by Bucher et al. Secondly,
the potential for modification of the result of the indirect
comparison can be explored using appropriate characteristics by
sensitivity analyses, subgroup analysis, or meta-regression, al-
though the usual limitations of these methods should be kept in
mind [56]. Nineteen reviews (44%) applied these methods in an
attempt to assess treatment effect modification.
Homogeneity should be assessed within the two trial sets that
contribute to the indirect comparison using the same methods as
for standard meta-analysis [4]. Statistical heterogeneity is assessed
by visually inspecting forest plots, using the Chi-square test, I-
squared statistic, and by interpretation of the between trial
variance estimate from a random effects model. Overall, only 24
reviews (60%) reported methods to assess statistical heterogeneity
or presented the results of such methods. Potential clinical and
methodological explanations for statistical heterogeneity can be
assessed using subgroup analysis, sensitivity analysis, or meta-
regression. In total, 19 reviews (59%) for which heterogeneity was
detected, did not investigate heterogeneity using these methods.
Patient characteristics and trial features should also be compared
across trials within each trial set. We found three reviews for which
a fixed effects model was adopted even though statistical
heterogeneity was evident. When high levels of unexplained
statistical heterogeneity exists a random effects model to account
for heterogeneity is more appropriate, or may even indicate that
meta-analysis is not appropriate.
Consistency between direct and indirect evidence from two-arm
trials can be assessed by comparing characteristics of direct and
indirect evidence trials and by using a hypothesis test to indicate
whether there is a significant discrepancy between the treatment
effect estimates calculated from each evidence type although the
test has low power [2,3,8,57]. We found one review (6%) of the 17
that had included direct and indirect evidence that applied this
method. A further five reviews (30%) assessed consistency using an
unspecified method. It is important that the cause of inconsistency
is investigated. Inconsistent evidence may signify bias from
methodological inadequacies in the direct or indirect evidence,
clinical diversity across patients or a combination of both [1–3].
Song et al showed that in some cases indirect evidence is less biased
than direct evidence [1]. Often the cause of inconsistency means
that combining direct and indirect evidence would be inappro-
priate. We found two reviews that reported inconsistency and
neither review combined evidence which is entirely reasonable.
When evidence is consistent, the generic inverse variance method
can combine direct and indirect evidence; however, the treatment
effect estimates from each evidence type should also be reported
separately for transparency. We found that four reviews reported
consistency and one of these combined the evidence.
With regard to interpretation, since indirect evidence is not
the same as direct evidence, this distinction should be stated to
avoid misinterpretation. We found 18 reviews (42%) that did not
make this distinction. When interpreting indirect evidence,
consideration should be given to the generalisability of the pa-
tients included in the trials involved in the indirect comparison,
just as the generalisability of patients included in trials in a direct
comparison should be considered when interpreting direct
evidence. Moreover, the results of the assessment of the assum-
ptions can help determine the reliability of the indirect evidence;
if the assumptions appear reasonable, the indirect evidence should
be valid. In the same way, the assessment of the homogeneity
assumption can help determine the reliability of the direct
evidence.
The results of the indirect comparison, direct comparison,
individual trial results, and the meta-analytic treatment effects
from each of the two trial sets involved in the indirect comparison,
should be reported. Also, review authors should clearly indicate
which results are based on indirect evidence; our findings showed
that 19 reviews did not make this indication.
One important aspect not examined in this review is that
indirect comparisons should be based on meta-analysis results
which are a component of a systematic review as for any other
meta-analysis. The usual rigorous methodology and assessment
of risk of bias should be undertaken as part of the systematic
review [58].
Comparison with existing evidence
The recently published article by Song et al included 88 reviews,
substantially more than the 43 reviews included in this overview
[6]. However, 14 reviews are included in this article that were not
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et al which are not included in this assessment. The reason for this
disparity is partly due to differences in eligibility criteria, search
strategies and search terms. Even so, the results of this review
mostly support the findings of Song et al but consider the quality of
aspects in more depth than previous research. Song et al found that
trial similarity was discussed or explicitly mentioned in 45% of
reviews, where as we found that 26% of reviews explicitly stated
the assumption. Song et al reported that 26% reviews carried out
subgroup or meta-regression to identify or adjust for possible
treatment effect modifiers; we found that 44% of reviews
undertook similar methods. We found that 26% of reviews
compared trial and patient characteristics across all the trials used
in the indirect comparison; Song et al stated that 30% of reviews
compared characteristics. Consistency of direct and indirect
evidence was assessed in 71% of reviews that applied the naive
approach or adjusted indirect comparison method as described by
Song et al, where as we established that 35% assessed the
consistency of evidence. Song et al found that 12% of these reviews
combined direct and indirect evidence; we found that 6% of
reviews combined evidence.
Song et al highlighted the methodological flaws in published
indirect comparisons and made recommendations regarding
suitable methodology. Our review identifies the importance of
improving reporting quality and adds empirical data to the
existing evidence regarding methodological quality. The specifi-
cally devised quality assessment criteria applied in this review
provides a grounding to help review authors carry out indirect
comparisons and to aid appropriate interpretation.
Limitations
The main limitation of this review is that generalisability is
restricted because reviews that compared more than two interven-
tions simultaneously, for example, using mixed treatment compar-
ison meta-analysis models were excluded because additional quality
criteria and search terms would apply to these reviews. Detailed
quality assessment criteria would include modelling details such as
allowance for multi-arm trials, specification of variance structures,
and assessment of consistency of indirect evidence using different
common interventions (that is, different loops of evidence in a
treatment network). For this reason, reviews that compared more
than two interventions simultaneously will be considered separately
followingasearchusingadaptedsearchterms.Intotal,21reviewsof
randomised trials using mixed treatment comparison methodology
were excluded from this overview. However, it is worth noting that
the methodology for undertaking a simple indirect comparison is
much more accessible than for complex mixed treatment
comparisons and therefore widely applicable. Interestingly, Song
et al reported that 63% of reviews applied the adjusted method or
naive approaches, where as only 20% of reviews compared multiple
treatments simultaneously using meta-analysis. These results show
that this article is applicable to the main body of published reviews.
A further limitation of this review is that we may not have
retrieved all published reviews including an indirect comparison
because some reviews may not have been indexed using the search
terms specified. However there is no reason to believe that the
reviews we identified would differ to those we did not identify and
hence our sample should be a representative sample of published
indirect comparisons in the medical literature. In fact the
conclusions reached in this article are comparable to the article
by Song et al although slightly different sets of reviews were
included in each article.
Lastly, a thorough assessment of quality would require clinical
knowledge of the individual review topic areas. Clinical knowledge
would allow assessment of the similarity assumption as potential
patient characteristics that could influence the result of the indirect
comparison may be known to those working within the individual
review areas.
In conclusion, indirect comparisons can be extremely valuable
and their use is increasing in the literature. However, the validity
of the indirect comparison relies on underlying assumptions
similar to standard meta-analysis. This review shows that these
assumptions are not routinely explored when undertaking and
reporting indirect comparisons. We recommend therefore, that the
methodological and reporting quality of indirect comparisons
should be improved and propose that the quality criteria applied
in this article may provide a basis to help review authors carry out
indirect comparisons and to aid appropriate interpretation.
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